Asset profile
cadisegliatin
Small molecule
Evidence outlook · registrational
Type 1 Diabetes: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-04.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
4 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 4 same-indication; 2 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Cadisegliatin: this drug | Phase 3 | Small molecule | — | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Sotagliflozin (Inpefa) | Approved | Small molecule | SGLT1/2 (dual) | ||
| Zimislecel | Phase 3 | Cell therapy | Pancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug) | ||
| BMF-219 | Phase 2 | Small molecule | Menin |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.